Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Giles Campion"'
Autor:
Nathalie M Goemans, Már Tulinius, Marleen van den Hauwe, Anna-Karin Kroksmark, Gunnar Buyse, Rosamund J Wilson, Judith C van Deutekom, Sjef J de Kimpe, Afrodite Lourbakos, Giles Campion
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0161955 (2016)
BackgroundDrisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.MethodsThis 188-week open-label extension
Externí odkaz:
https://doaj.org/article/3e55aff068e14473843a4a30a61a1672
Autor:
David A. Rider, Mona Eisermann, Kathrin Löffler, Manuela Aleku, Daniel I. Swerdlow, Sibylle Dames, Judith Hauptmann, Eliot Morrison, Marie Wikström Lindholm, Steffen Schubert, Giles Campion
Publikováno v:
Atherosclerosis. 349:240-247
The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we describe the pharmacological data for SLN360, a GalNAc-conjugated siRNA targeting LPA, design
Autor:
David Rider, Simon Chivers, Julia Aretz, Mona Eisermann, Kathrin Löffler, Judith Hauptmann, Eliot Morrison, Giles Campion
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 189(2)
SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing lipoprotein (a)-related cardiovascular risk. Here, we describe the findings from key preclinical safety studie
Autor:
Daniel Swerdlow, Sandra Revill Tremulis, Marlys Koschinsky, Giles Campion, Emma Green, Rosamund Wilson, Jessica Pacey, Henry Ginsberg
Publikováno v:
Journal of Clinical Lipidology. 15:e17
Autor:
Nathalie Goemans, Eugenio Mercuri, Elena Belousova, Hirofumi Komaki, Alberto Dubrovsky, Craig M. McDonald, John E. Kraus, Afrodite Lourbakos, Zhengning Lin, Giles Campion, Susanne X. Wang, Craig Campbell, A. Araujo, E. Bertini, P. Born, C. Cances, B. Chabrol, J.-H. Chae, J. Colomer Oferil, G.P. Comi, J.-M. Cuisset, G. D'Anjou, I. Desguerre, R. Erazo Torricelli, R. Escobar, D. Feder, A. Ferlini, R. Giugliani, E. Henricson, A. Herczegfalvi, Y.-J. Jong, S. Kimura, J.-B. Kirschner, K. Kleinsteuber, A. Kostera-Pruszczyk, M. Kudr, W. Mueller-Felber, E.H. Niks, K. Ogata, C. Palermo, M. Pane, I. Pascual, Y. Pereon, S. Raskin, M. Rasmussen, U. Reed, U. Schara, K. Selby, C. Sobreira, Y. Takeshima, J.J. Vilchez Padilla, G. Vita, P. Vondracek, G. Wiegand, E. Wilichowski
Publikováno v:
Paediatrics Publications
Neuromuscular Disorders
Neuromuscular Disorders, 28(1), 4-15
Neuromuscular Disorders
Neuromuscular Disorders, 28(1), 4-15
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous drisapersen 6 mg/kg/week in 186 ambulant boys aged >=5 years, with Duchenne muscular dystrophy (DMD) resulting from an e
Autor:
Karen, Anthony, Virginia, Arechavala-Gomeza, Laura E, Taylor, Adeline, Vulin, Yuuki, Kaminoh, Silvia, Torelli, Lucy, Feng, Narinder, Janghra, Gisèle, Bonne, Maud, Beuvin, Rita, Barresi, Matt, Henderson, Steven, Laval, Afrodite, Lourbakos, Giles, Campion, Volker, Straub, Thomas, Voit, Caroline A, Sewry, Jennifer E, Morgan, Kevin M, Flanigan, Francesco, Muntoni
Publikováno v:
Neurology
Objective: We formed a multi-institution collaboration in order to compare dystrophin quantification methods, reach a consensus on the most reliable method, and report its biological significance in the context of clinical trials. Methods: Five labor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2ec0a919ae291bbf623377c22a608f4b
http://nectar.northampton.ac.uk/10559/1/Anthony_et_al_Neurology_BOM_study.pdf
http://nectar.northampton.ac.uk/10559/1/Anthony_et_al_Neurology_BOM_study.pdf
Autor:
Peter T. Klouda, David M. Sansom, Peter J. Maddison, Jeffrey L. Bidwell, Giles Campion, Ben A. Bradley
Publikováno v:
Human Immunology. 19:269-278
HLA DQ alpha and DQ beta cDNA probes were used to study TaqI generated restriction fragment length polymorphisms (RFLPs) in DR4-positive patients with Felty's syndrome (FS), seropositive rheumatoid arthritis (RA), and in HLA-DR4 positive controls. Th